Premium
Certain public‐reported immune‐mediated adverse events for PD‐1 inhibitors in melanoma occur at higher rates than in clinical trials
Author(s) -
Gupta N.,
Cullison C.,
Mally A.,
Xiang L.,
Hill S.T.,
Beveridge M.G.
Publication year - 2021
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.17373
Subject(s) - medicine , adverse effect , melanoma , clinical trial , immune system , intensive care medicine , medline , oncology , immunology , cancer research , political science , law